Clearmind’s CMND-100 Clears Safety Hurdle in FDA Trial — Clearmind Medicine Inc.

Event summary

Clearmind’s CMND-100 completed Part A of its Phase I/II FDA trial with no serious adverse events across four dose cohorts (20mg to 160mg).
All 24 participants successfully finished treatment as planned, reinforcing the drug’s safety and tolerability.
The non-hallucinogenic neuroplastogen approach aims to avoid regulatory hurdles tied to classical psychedelics.
Next steps include advancing to dosing AUD patients, pending full dataset review.

The big picture

Clearmind’s positive Phase I/II results for CMND-100 mark a critical milestone in developing non-hallucinogenic treatments for Alcohol Use Disorder. The trial’s success underscores the potential of neuroplastogens to bypass regulatory and practical challenges associated with classical psychedelics, positioning Clearmind as a key player in the emerging neuroplasticity-focused therapeutics market.

What we're watching

Regulatory Advantage: Whether CMND-100’s non-hallucinogenic profile will accelerate FDA approval compared to psychedelic alternatives.
Clinical Progression: The pace at which Clearmind advances to Part B of the trial and begins dosing AUD patients.
Market Differentiation: How CMND-100’s safety data positions it against competitors in the neuroplastogen space.